Member Info for Moneymunch

News on the status of the Covid-19 trial surely must be imminent, and plenty of other news on the rest of the pieline must be close. SFX-01 has been in evaluation for multiple disease targets for clinical trials from several academic research organisations since the start of the year and so news could drop at anytime, as well as the high profile breat cancer research, which is now in the planning for phase 2b trials with Manchester Unversity, and the following outlines the planned work programme and so news on the progress very likely. I aslo think there is a high chance of news on a strategic investor or early commercial JV which would certainly explain the massive share transfer/accumulation over several months or at least a TR1 at the very least with disclosure of who or why!!!??? Gl ;-)

.........

Breast Cancer Current and planned work programme

All preclinical breast data published in high impact journal in June 2020

Extensive review of clinical pathway to approval close to completion

Supplementary preclinical work required to confirm CDK4/6i “resistance-breaking” hypothesis

New “commercial ready” solid tablet formulation to be completed in H3 2020

Non-dilutive capital e.g. partnering to fund the next trial(s)

Targeting CTA/IND in H1 2021 with first patient first dose in Q2/Q3 2021

http://evgen.com/wp-content/uploads/2020/07/EVG-AGM-presentation-2020-16Jul20.pdf

I reckon we should have a good day today from those anticapating news this coming week, the chart couldn't looked more primed for the next leg UP. ;-)

SFX-01's Covid-19 patient trial is phase 2/3 which is "Phase 2 and 3 Combination Design to Accelerate Drug Development ", we already know that SFX-01's safety profile is safe and sound from SFX-01's phase 2 SAH and SFX-01's phase 2 breast cancer trials, and so if an early therapeutic benfit is observed in the Covid-19 trials, then presumably the trial will be accelerated into phase 3.......Top Line results are expected September 2021, but no doubt early reporting will be made on any positive indications from the phase 2 stage of the trial.......news next week that the trial is already in progress would be very well received. Gla ;-)

"with patients offered the chance to participate immediately after their diagnosis"

The primary outcome of the trial is the clinical status of patients on day 15 based on a seven point scale, recommended by the World Health Organisation as the optimal clinical trial endpoint for COVID-19 studies.

Extremely grim news and worrying for all, but no shortage of patients for SFX-01's long awaited Covid-19 patient trials...here's hoping Evgen and other UK Bio's zuch as SNG can come up with an effective treatment or two. Gl :-)

........

Hospitals in England now have more coronavirus patients than they did when lockdown restrictions were first announced in March, a senior NHS official has revealed.

And with admissions rising, numbers of Covid-19 patients in the worst-hit region of the northwest could within four weeks top the levels seen during the peak of the first wave in the spring.

The medical director of NHS England, Prof Stephen Powis, said that without additional measures to control the spread of the disease, deaths would rise to a level “too great to bear”

Prof Powis dismissed as “wishful thinking” claims that elderly and vulnerable people could be shielded from the rising rates of infection among the younger population.

Details of the surge in infections were revealed as NHS Nightingale hospitals in Manchester, Sunderland and Harrogate were ordered to mobilise to prepare for a second wave of patients overwhelming NHS capacity in the north of England.

It came as Boris Johnson chaired a meeting of the government’s Cobra emergencies committee ahead of today’s announcement of a new three-tier system of restrictions, expected to include the closure of pubs and bars in the worst-hit parts of the country.

Looking very good and very strong....Gla ;-)))

Share Code 900 earlier, if you believe in that sort of thing....Gla ...On and UP!!!.;-)

900 - Allow the stock to float and trade freely.

Tech

British billionaire Jim Mellon plans to take his life extension start-up public in six to 12 months

Key Points

British billionaire Jim Mellon says he expects to take his life extension company Juvenescence public in the next six to 12 months.

He told CNBC that Juvenescence has identified the investment banks it wants to work with.

Juvenescence is investing in a wide range of anti-ageing therapies in the hope that one or two ideas end up working.

Juvenescence, which has 29 employees in London, has raised about $170 million privately and Mellon said it still has a “fair amount of money left in the bank.” Other billionaires, including Mike Cannon-Brookes, the co-founder of Australian software firm Atlassian, and NEX Group founder Michael Spencer, have invested in the company.

https://www.cnbc.com/2020/09/29/billionaire-jim-mellon-plans-to-take-life-extension-start-up-public.html

Billionaire Antiaging Investor Jim Mellon Predicts We Will Live to 115-150 Years

Brian Wang | February 26, 2019 

 

Jim Mellon is a billionaire investor in antiaging companies. Jim has made several investments in antiaging companies and as one of the leading investors in the field gets pitched almost all of the antiaging companies. Jim thus has a unique perspective on what the latest developments are with anti-aging technology. Jim predicts that average life expectancy will be 115 years by 2050 while today it is about 80 years. Gene therapy will extend that to 150 years. He predicts there will be significant new developments in the next few years alone. Jim predicts that in ten to fifteen years cancer will mostly become a manageable chronic condition in the cases where it is not completely cured.

Jim predicts there will be a large improvement in overall public health from a wave of new biotech treatments and drugs within the next five years.

There will also be a larger improvement in health from gene editing, stem cells and full tissue regeneration, organ transplantation from animals into humans.

The past six years has seen the emergence of the cure for hepatitis C, cancer immunotherapy, curing leukemia, and CRISPR CAS9 gene editing.

Jim Mellon spoke at the antiaging conference Raadfest 2018.

Jim pointed out that the current global market for anti-aging products is about $140 billion but nothing actually works in terms of extending lifespan. He predicts that there will soon be effective life-extending products and treatments. This will cause the biggest stock market mania in history.

Juvenescence (aka antiaging) will become the biggest industry on the planet.

Potential transformational news stacking up.....SFX-01's phase 2 breast cancer results were outstanding .......news of their phase 2b trials coming soon and every chance of a commercial JV in the pipeline given that the results were "life changing for some patients"....exciting times...;-)

hTtps://twitter.com/robclarkelab?lang=en

Rob Clarke Retweeted
Ed Tate
@TateScience
·
Jul 3

Read new #breastcancer research from @MCRBreastCentre with contributions from @tatescience & others, on targeting STAT3 signalling in ER+ breast cancers in @oncogenejournal

htTps://rdcu.be/b5pdf

Targeting STAT3 signaling using stabilised sulforaphane (SFX-01) inhibits endocrine resistant stem-like cells in ER-positive breast cancer

......................

Rob Clarke
@RobClarkeLab
·
Jun 24
We’re looking for a talented student to carry out a PhD starting this September: Understanding the role of STAT3 in therapy-resistance and metastatic progression of breast cancer (MRC CASE) at The University of Manchester on hxxp://FindAPhD.com

About the Project

Resistance to endocrine and other therapies during metastatic progression is the major cause of mortality in breast cancer. We have previously reported that endocrine resistance can be driven by ALDH+ breast cancer stem cells (CSCs) and more recently that STAT3 is activated in these cells (Simoes et al., 2015 and 2020). We and others have reported that breast cancers resistant to the recently FDA-approved CDK4/6 inhibitors such as Palbociclib have increased numbers of CSCs and activation of STAT3 signalling, and that inflammatory and obesity-related breast cancer are driven by IL6 and leptin activating STAT3 transcriptional activity.

Our hypothesis is that targeting STAT3 would benefit breast cancer patients where CSCs are driven by the STAT3 signalling pathway, and in particular would combat therapy resistance and metastatic progression. In the Clarke lab, we have established in vitro and in vivo models of breast cancer patient-derived organoids and xenografts that metastasise to relevant organs such as lung and bone (Byrne et al., 2017, Eyre et al., 2019). The student will use these models to perform CSC assays, gene and protein expression analyses to characterise the signalling pathways targeted by SFX-01 and discover biomarkers that predict response.

The potential outcome is the definition of which breast cancers have STAT3 dependency and are sensitive to STAT3-targeted therapies. We aim to understand the mechanisms of STAT3 signalling and establish predictive biomarkers that will have translational value in precision medicine clinical trials, which the appointed student would help design during a placement in the iCASE partner company Evgen Pharma PLC, who aim to develop SFX-01 for improved breast cancer therapy.

hTtps://www.findaphd.com/phds/project/understanding-the-role-of-stat3-in-therapy-resistance-and-metastatic-progression-of-breast-cancer-mrc-case/?p122397

James D Chalmers Retweeted
Peter Horby
@PeterHorby
·
8h
RECOVERY publication on hydroxychloroquine finally out. Hydroxychloroquine is not effective in hospitalised COVID patients. Disappointing, but allows us to focus our efforts on promising new treatments.

htps://nejm.org/doi/full/10.1056/NEJMoa2021436?query=featured_coronavirus

https://twitter.com/profjdchalmers?lang=en

and it keeps on rising :-(

Scottish numbers:

8 October 2020

Summary 1,027 new cases of COVID-19 reported; this is 13.5% of newly tested individuals

5 new reported death(s) of people who have tested positive31 people were in intensive care yesterday with recently confirmed COVID-19

377 people were in hospital yesterday with recently confirmed COVID-19

18,796 new tests for COVID-19 that reported result

.............................

Scottish numbers:

30 September 2020

640 new cases of COVID-19 reported; this is 10.3% of newly tested individuals.

7 new reported death(s) of people who have tested positive

15 people were in intensive care yesterday with recently confirmed COVID-19.

137 people were in hospital yesterday with recently confirmed COVID-19.

15,629 new tests for COVID-19 that reported results.

I don't know the significance either, but wouldn't delay too much for a top up with news expected imminently.

ps fairview, given the rise in numbers , SFX-01's patient trials could already be underway and it would be stellar news if they were to announce that all 300 patients were administered as opposed to first patient administered.....exciting times regardless with plenty of news likely from across Evgen's multiple disease pipeline.....and current sp and market cap does not reflect true and fair value of prospects at hand....Gl ;-)

0  0 0

One thing for sure, is that if SFX-01's phase 2/3 Covid-19 patient trials were successful and SFX-01 was confirmed a therapeutic benefit for the effects of ARDS/ Covid-19, then Evgen's market cap would be valued in $100's of millions as opposed to its current £17m....undoubted Transformational potential on several fronts...Excitement cranking UP as we await an imminent UPdate on proceedings. Gla :-)

Ps Every chance!!! :-)

“It is crucial to understand the most appropriate context for introducing an anti-inflammatory therapy to complement an antiviral therapy. Such therapy must control inflammation without altering the ability of the host to mount an efficient adaptive immune response against the virus.

We propose that boosting endogenous cellular defenses by targeting the cytoprotective transcription factor Nrf2 (gene name NFE2L2) will promote the resolution of COVID-19 associated inflammation and also restore redox homeostasis and facilitate tissue repair.

The isothiocyanate sulforaphane (SFN) is the most potent naturally occurring NRF2 activator, with well-documented antioxidant and anti-inflammatory effects. The high bioavailability of SFN makes it an excellent candidate for alleviating excessive anti-inflammatory responses and protecting the lungs.

Even though Nrf2 is the primary mediator, additional factors contribute to the anti-inflammatory effects of SFN. SFN inhibits NF-?B, inhibitor of NF-?B kinase subunit ß (IKKß), and STAT3.

By regulating the endogenous cytoprotective systems, Nrf2 may have a more physiological role in achieving a balance between the beneficial and adverse effects of inflammation. Nrf2 inhibits IL-6 and IL-1ß gene expression.

Antioxidant and cytoprotective effects of Nrf2 activation are long-lasting and persist for several days after inducer elimination. They are mediated by enzymes that, in contrast to small molecules, have long half-lives and are not consumed, and are instead regenerated during the reactions which they catalyze.”

hTtps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7359808/ “Can Activation of Nfr2 Be a Strategy against COVID-19?"

With the surge of new cases, news of SFX-01's Covid-19 Patient trials must be imminent imho....and the following adds weight to SFX-01's prospects in treating ARDS/Covid-19 being a potent activator of Nrf2. Gla ;-)

Multiple sclerosis drug dimethyl fumarate may suppress viral multiplication and reduce inflammation in COVID-19 patients

October 05, 2020 22:00:31 IST

A number of drugs like remdesivir specifically target the RNA polymerase of SARS-CoV-2, causing it to stop multiplying while other drugs like hydroxychloroquine focus on reducing inflammation, a possible cause of death in coronavirus patients.

COVID-19 is a viral disease caused by the SARS-CoV-2 virus. Since the disease is still new and viruses are intracellular parasites (they need a living host to survive), scientists are studying how the virus works, as extensively as possible, so an effective antiviral therapy or drug can be developed against it.

A number of drugs like remdesivir specifically target the RNA polymerase of SARS-CoV-2, causing it to stop multiplying while other drugs like hydroxychloroquine focus on reducing inflammation, a possible cause of death in coronavirus patients.

Now, a group of researchers at the Aarhus University, Denmark claim that a multiple sclerosis drug called dimethyl fumarate (DMF) can suppress the growth of a wide range of viruses including the COVID-19 causing virus SARS-CoV-2 and may hence be effective in the treatment of the disease.

The findings of the research study are published in the peer-reviewed journal Nature Communications.

Multiple sclerosis is a chronic condition of the central nervous system in which a person’s own immune system attacks and damages the brain cells, causing symptoms like fatigue, pain, muscle stiffness and spasms, numbness, tingling, depression and anxiety.

NRF2, 4-octyl-itaconate and DMF

NRF2 is a protein that is involved in the process of transcription (conversion of DNA to RNA) in body cells. During homeostasis (normal conditions) another compound called KEAP1 ensures that NRF2 is present in its inactive state inside the cell. However, when oxidative stress increases, KEAP1 gets inactivated and NRF2 activates. The latter then leads to the transcription of certain genes that can prevent tissue damage caused due to infection. NRF2 also regulates inflammation by suppressing the production of certain inflammatory compounds like interleukin (IL-) 1beta.

Oxidative stress is a term used to denote the imbalance between free radicals and antioxidant compounds in our body. The condition generally leads to tissue damage.

Previous studies have shown that small molecules, including itaconate and fumarate, can induce NRF2 to help manage inflammation. 4-octyl-itaconate, specifically, was shown to be an effective inducer of NRF2. DMF has been approved by the US Food and Drug Administration for the treatment of multiple sclerosis as the condition is marked by inflammation.

https://www.firstpo

Lol..... :-))))

No sprig of broccoli in his lapel then??? ;-)

I reckon that there's very few shares in free float as I'm fairly certain that there has been an orderly share transfer/ accumulation in progress for months, plenty have parted with their shares cheaply over that time and all shares sold have been mopped UP cheaply.....all suggestive of a strategic investor JV partnership imho, although whatever the reason, this will re-rate suddenly and significantly when good news drops with so few shares available and with so much potential news possible from Evgen's multiple disease pipeline, the opportunity for Transformational returns in the coming weeks and months look firmly in our favour. Gla :-)

Looking good and strong in anticiation of positive news.....perfectly poised and primed...Gla Holders...On and UP!!!;-)

A huge spike in Covid-19 numbers across the UK reported today, and here's the Scottish numbers compared to a week ago which is worrying for all....and so confirmation that SFX-01's patient trials are underway and first patients have been administered must be imminent imho...Gla :-)

Scottish Numers 6/10/20

Summary

800 new cases of COVID-19 reported; this is 13.2% of newly tested individuals

2 new reported death(s) of people who have tested positive

25 people were in intensive care yesterday with recently confirmed COVID-19

262 people were in hospital yesterday with recently confirmed COVID-19

13,992 new tests for COVID-19 that reported results

......

Scottish numbers:

30 September 2020

640 new cases of COVID-19 reported; this is 10.3% of newly tested individuals.

7 new reported death(s) of people who have tested positive

15 people were in intensive care yesterday with recently confirmed COVID-19.

137 people were in hospital yesterday with recently confirmed COVID-19.

15,629 new tests for COVID-19 that reported results.

Back into the swing of work today with a

@RobClarkeLab

lab meeting! 20 of us on Zoom, meeting our new students and summarising our research projects. It’s good to be back! #cancerresearch